Volume | 66,336 |
|
|||||
News | - | ||||||
Day High | 3.249 | Low High |
|||||
Day Low | 2.93 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
CASI Pharmaceuticals Inc | CASI | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
3.08 | 2.93 | 3.249 | 3.03 | 3.18 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
674 | 66,336 | $ 3.05 | $ 202,126 | - | 1.6008 - 8.48 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:44:58 | 54 | $ 3.0297 | USD |
CASI Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
40.09M | 13.32M | - | 43.11M | -41.01M | -3.08 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
CASI Pharmaceuticals News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CASI Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 4.74 | 4.78 | 2.93 | 3.64 | 100,344 | -1.71 | -36.08% |
1 Month | 5.76 | 6.86 | 2.93 | 5.56 | 565,698 | -2.73 | -47.40% |
3 Months | 6.58 | 8.19 | 2.93 | 5.66 | 217,703 | -3.55 | -53.95% |
6 Months | 2.18 | 8.48 | 1.90 | 5.53 | 124,816 | 0.85 | 38.99% |
1 Year | 1.68 | 8.48 | 1.6008 | 4.92 | 78,263 | 1.35 | 80.36% |
3 Years | 24.00 | 24.40 | 1.45 | 12.93 | 614,426 | -20.97 | -87.38% |
5 Years | 32.70 | 39.00 | 1.45 | 15.81 | 477,570 | -29.67 | -90.73% |
CASI Pharmaceuticals Description
CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing innovative therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA. The company primarily operates in the United States, Canada, China and other parts of the world. |